About Gregor Diagnostics
Gregor has developed a proprietary system to maintain biomarker stability in the seminal fluid. This will allow samples to be collected in the comfort of the patient's home and shipped back to Gregor's laboratory.
Better Screening for Prostate Cancer.
Gregor Diagnostics Inc. is a molecular diagnostics company dedicated to revolutionizing prostate cancer screening. Based in Madison, Wisconsin, the company focuses on developing a groundbreaking, patient-friendly test designed to detect prostate cancer at its earliest stages.
Our goal is to transform the standard of care for prostate cancer by providing a diagnostic tool that can differentiate between indolent (slow-growing) and aggressive cancer upon detection. By identifying the severity of the disease early, we aim to:
- Decrease the overdiagnosis and overtreatment of indolent prostate cancer.
- Enable more effective detection and clinical management of aggressive cases.
- Improve long-term patient outcomes through early, accurate intervention.
Screening is Declining
Because the PSA test is no longer recommended, screening rates of men in the United States have declined. Lower screening reduces the overdiagnosis and overtreatment of Prostate Cancer as intended by the recommendation. However, by screening less men for Prostate Cancer, the aggressive cancers will also be missed. This will trigger more deaths that could have been avoided.
Let's not abandon screening; let's build a better screening test.
